TSXV:BTI.H - Post by User
Post by
Boomskidon Mar 01, 2023 12:05pm
188 Views
Post# 35312697
Sangamo
SangamoBioasis has no immediate interest in Sangamo or any other reported efforts to treat Fabry disease.
If Chiesi (and Protalix) move forward with an xB3 version of PRX-102 for Fabry, the most that Bioasis can gain would be (maybe) a couple of millions in milestone payments in the immediate 2 or 4 years.
Bioasis has already, totally and finally, sold those four LSDs and has nothing else to gain from the deals other than what is likely a low single digit (1% ??) royalty that won't kick in for years.
Each Chiesi LSD was worth an average of $750,000 each, with an average of $34.5 million in milestones, almost entirely payable in late stage clinical trials and upon commercialization if the xB3 drug gets approved in 5 or more years at the earliest.
There are many companies working on Fabry, one of which is Sangamo. Because Bioasis has almost certainly sold xB3 for Fabry to Chiesi, Sangamo's work may affect Chiesi, but it will have no impact on Bioasis.
jd